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INTRODUCTION 
 Lung cancer ranks among the most common and most lethal 
malignancies worldwide. It is rapidly emerging as a major cause of mortality in 
the Middle East, Africa, and Asia as well; and is increasingly being recognized 
in India[2]. Death rates attributable to this disease are expected to increase 
substantially over the next several decades[3]. 
 Procedures used to diagnose bronchopulmonary neoplasms should be as 
accurate as possible and should provide optimum characterization of the tumor 
type. Fibreoptic bronchoscopic biopsy refers to the bronchoscopic technique of 
obtaining pulmonary parenchymal tissue for histological analysis. It is one of 
the common modality used to diagnose lung cancer and is the best technique 
for obtaining specimens to diagnose endobronchial lung carcinoma. The lesion 
can be visualized and the location of the specimen can be mapped precisely 
with a fibreoptic bronchoscope. 
 The histopathologic distinction of small cell from non–small cell 
carcinoma of lung is important therapeutically. However, such distinction may 
not always be straightforward based on morphologic findings alone, especially 
in cytologic specimens, but in tissue specimens as well. 
 p63 is a recently discovered member of the p53 family that has been 
shown to be important in the development of epithelial tissues. p63 may also 
play a role in squamous cell carcinomas of the lung, head and neck, and cervix, 
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and its expression is increased in these tumors[1]. The purpose of this study 
was to analyse the demographics, risk factors, distribution of lung carcinomas 
and to investigate the expression of p63 in various histologic types of lung 
tumors and correlate with histological gradings.  
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AIMS AND OBJECTIVES 
1. To estimate the incidence of carcinomas in patients attending chest 
clinic. 
2. To analyse the demographics, risk factors and distribution of lung 
carcinomas. 
3. To study the expression of p63 in different histologic types of lung 
carcinomas.  
4. To correlate histological grade with expression of p63 in fibreoptic 
bronchoscopic biopsy specimens. 
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REVIEW OF LITERATURE 
 Lung cancer is the most frequent and one of the most deadly cancer 
types, with more than 1.1 million deaths annually worldwide. In men, 85-90% 
of cases can be attributed to tobacco smoking. Despite innovations in 
diagnostic testing, surgical technique, and the development of new therapeutic 
agents, the five-year survival rate has remained about 13–15% throughout the 
past three decades[4]. 
 Factors contributing to the low lung cancer survival rate include the 
small proportion of patients presenting with resectable disease and 
chemotherapy response rates ranging from 13–42% in patients with advanced 
stage disease[5]. 
 Although the lung is an organ in which many histological types of 
malignant epithelial tumor can develop, about 95% of cancers occurring there 
are of four major histological types: squamous cell carcinoma, small cell 
carcinoma, adenocarcinoma and large cell carcinoma. The distinction between 
these four major types of lung carcinoma on routine bronchoscopic biopsies 
sometimes presents diagnostic problem. Materials obtained under fiberoptic 
bronchoscopic guidance are often very small and are sometimes crushed, 
particularly in the case of small cell carcinoma. Also, in small tissue fragments, 
differentiated tumor features (such as a glandular structure or keratinization) 
may not be presented. Histological diagnosis of large cell carcinoma is made 
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after the exclusion of squamous cell carcinoma, small cell carcinoma, 
adenocarcinoma, and other lung cancers of a specific type (especially main 
groups like large cell neuroendocrine carcinoma and carcinoids)[6] 
NORMAL LUNG 
 The lung consists of airways, blood vessels, the connective tissue 
framework and the pleura[7]. 
Airways 
 Airways include the trachea, bronchi, bronchioli, and acini. The main 
bronchi branch dichotomously and give rise to gradually smaller and smaller 
bronchi. On an average there are 16 generations of bronchi and bronchioles 
before the first respiratory bronchioles are reached, but the number of 
generations varies approximately from 8 to 23 in different regions of lung. 
 The walls of the trachea and main bronchi are reinforced by C shaped 
rings of cartilage anteriorly and laterally with a sheet of transverse smooth 
muscle filling the gap posteriorly. As the successive generations of bronchi 
become smaller, they are reinforced by progressively smaller and fewer islands 
of cartilage. The smooth muscle continues as bundles that wind in a spiral 
down the intrapulmonary bronchi, which extend into gradually narrower and 
narrower airways. 
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 The mucosa of the trachea and bronchi are lined by a pseudostratified 
ciliated columnar epithelium. By electron microscopy, four cell types can be 
recognized in the bronchial epithelium – ciliated cells, mucous cells, 
neuroendocrine cells and basal cells. Ciliated cells account for more than 90% 
of all bronchial cells. Mucous cells are filled with mucin rich granules. Their 
cytoplasm extends to the luminal surface. Neuroendocrine cells contain round 
neuroendocrine cytoplasmic granules. 
 The basal cells are small, triangular cells with relatively few organelles, 
which are attached to the basal lamina with hemidesmosomes and to the 
neighboring columnar cells by desmosomes. 
 The bronchial glands are located in the lamina propria of the bronchi. 
These glands are compound tubuloacinar structures composed of three cell 
types. 
1) Mucous cells, the cytoplasm of which is filled with weakly basophilic 
secretory vacuoles; 
2) Serous cells, the apical cytoplasm of which contains eosinophilic 
granules 1 to 2 micrometre in diameter. 
3)  Myoepithelial cells, which form a contractile network enclosing the 
glands. The myoepithelial cells resemble smooth muscle 
ultrastructurally and contain smooth muscle actin isoforms. 
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 Bronchi extend into bronchioles. The walls of bronchioles are devoid of 
both cartilage and glands and consist of only smooth muscle and connective 
tissue. The simple columnar epithelium lining the bronchioli is composed 
mainly of ciliated epithelial cells interspersed with non – ciliated secretory cells 
called clara cells. These bronchioles divide and give rise to respiratory 
bronchioles. The epithelium of respiratory bronchiole is continuous with that of 
alveoli. 
 The alveoli are airspaces lined by thin walls composed of capillaries 
covered by epithelium and supported by a delicate mesh of connective tissue. 
The alveolar lining consists predominantly of type 1 epithelial cells, which 
cover 98% of alveolar surface. Interspersed between these cells are small 
cuboidal epithelial cells, type 2 cells. Type 2 cells are characterized by a 
microvillous surface and cytoplasmic lamellar bodies, which contain alveolar 
surfactant. 
Pulmonary vasculature 
 The lungs have a dual blood supply: functional circulatory system 
comprising of pulmonary artery and its branches and the nutritional system 
originating from bronchial arteries. The pulmonary artery extends into branches 
that enter the lung accompanying the bronchi and run with them in the lung 
enclosed by a common sheath of adventitial connective tissue. The smallest 
branches of the pulmonary artery enter the acinus with the respiratory 
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bronchioles giving rise to precapillary arterioles, which accompany the alveolar 
ducts. The pulmonary veins lie at the periphery of the acini, often with 
connective tissue septa that divide the parenchyma into lobules. One vein 
drains two or more acini. The bronchial arteries originate from the thoracic 
aorta. The branches of the bronchial arteries run along the bronchial tree down 
to the level of respiratory bronchioles, whereupon they form capillaries that 
anastomose with the branches of the pulmonary artery. 
Bronchus associated lymphoid tissue 
 Immune system of lung is represented by lymphoid nodules associated 
with the bronchioles, lymphnodes at the bifurcations of the bronchi and by 
lymphocytes, plasma cells and mast cells diffusely scattered through out the 
mucosa of the bronchi[8]. 
Pleura 
 The pleural investment of lung is composed of alternating layers of 
collagen and elastic fibers covered by a single layer of epithelium called 
mesothelium because of its mesodermal origin. 
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CLASSIFICATION OF LUNG TUMOURS 
 Tumors of the lungs can be classified clinically, histogenetically, or 
pathologically into several categories. Clinically, the tumors may be 
symptomatic or asymptomatic, benign or malignant. Histogenetically, the 
tumors may be classified according to their provenience, as originating from 
the bronchi, bronchioles, pulmonary connective tissue and blood vessels, or 
pleura. Pathologic classification may be based on microscopic features. On the 
basis of location, the tumors may be classified as central or peripheral, 
localized or diffuse, solitary or multiple. 
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WHO CLASSIFICATION OF PRIMARY LUNG TUMORS[9] 
 
  
Epithelial tumors Non- Epithelial tumors 
A. Benign tumors 
1. Papillomas 
2. Adenomas 
a. Pleomorphic adenoma 
b. Monomorphic adenoma 
B. Dysplasia/Carcinoma in situ 
C. Malignant tumors 
 1. Squamous cell carcinoma 
(epidermoid carcinoma) 
 2. Small cell carcinoma 
  a. Oat cell carcinoma 
  b. Intermediate cell type 
  c. Combined oat cell carcinoma 
 3. Adenocarcinomas 
  a. Acinar adenocarcinoma 
  b. Papillary adenocarcinoma 
  c. Bronchioloalveolarcarcinoma 
  d. Solid carcinoma with mucus 
                              formation 
              4. Large cell carcinoma variants 
  a. Giant cell carcinoma 
  b. Clear cell carcinoma 
 5. Adenosquamous carcinoma 
 6. Carcinoid tumor 
 7. Bronchial gland carcinomas 
  a. Adenoid cystic carcinoma 
  b. Mucoepidermoid carcinoma 
 8. Others 
• Soft tissue tumors primary 
in lung 
 
• Pleural tumors 
A. Benign 
mesothelioma 
B. Malignant 
mesothelioma 
 
• Miscellaneous tumors 
 
A. Benign tumors 
B. Malignant tumors 
 
1. Carcinosarcoma 
2. Pulmonary blastoma 
3. Malignant 
melanoma 
4. Malignant 
lymphoma 
5. Others 
 
• Unclassified tumors 
 
• Tumor like lesions 
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 Most of the malignant tumors of the lower respiratory tract are called 
bronchogenic carcinomas because they originate from the epithelium of 
bronchi.  They result from the malignant transformation of bronchial stem cells 
or their immediate descendents and are therefore composed of cells that are 
normally found in the bronchial epithelium. Tumors composed of ciliated or 
mucous cells are classified as adenocarcinoma; those composed of 
neuroendocrine cells, as small cell carcinomas; whereas those that are not 
committed or do not show such differentiation are classified as large cell 
carcinomas. Squamous cell carcinomas originate from foci of squamous 
metaplasia that are common in smokers. 
 SQUAMOUS CELL CARCINOMA 
 20% to 35% of all lung tumors are squamous cell carcinomas. Two 
thirds of squamous cell carcinomas are central tumors involving main and lobar 
bronchi. Gross appearance is not distinctive. The expectoration of keratinous or 
necrotic material may produce cavities within the tumor. Microscopic diagnosis 
depends on the identification of either intercellular bridges or keratinization. 
Keratinized cells are recognized by their brightly eosinophilic cytoplasm and 
pyknotic nuclei. The cells are arranged in nests that palisade at periphery of the 
lobules and become enlarged and flattened centrally. Whorls or eddies of cells 
may be keratinized (epidermoid pearls)[10]. 
 
  12
ADENOCARCINOMA 
 Adenocarcinomas account for one third of all lung tumors. They appear 
as discrete masses, usually at the periphery. Microscopically, they are highly 
variable in appearance. According to the WHO classification, four subtypes are 
recognized.  1)  acinic or glandular, 2) papillary, 3) bronchioloalveolar and 4) 
solid adenocarcinoma. Bronchioloalveolar carcinoma is the most common. It 
has a tendency to spread through the lungs along the existing air space walls, 
which serve as stroma for the tumor. The walls of alveoli, alveolar ducts are 
lined by malignant epithelial cells that vary in shape from cuboidal to 
columnar[11].  
LARGE CELL CARCINOMA 
 Large cell carcinomas comprise 7% to 15% of lung carcinomas. They 
are composed of relatively large cells that lack specific features by which they 
could be assigned to either the squamous or adenocarcinoma group. There are 
two variants.  
 Giant cell carcinoma is a highly malignant form of undifferentiated 
carcinoma composed of huge, poorly cohesive cells with eosinophilic 
cytoplasm and one or several large convoluted nuclei. Clear cell carcinomas are 
composed of cells with clear cytoplasm that is rich in glycogen[12]. 
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ADENOSQUAMOUS CARCINOMA 
 1% to 3% of lung carcinomas have clear evidence of both keratinization 
and glandular or secretory differentiation. Most are peripheral tumors 
associated with scars. 
SMALL CELL CARCINOMA 
 Small cell carcinomas account for 15% to 20% of lung carcinomas. 
Grossly, they appear as fleshy encephalad tumors forming nodules or 
infiltrating lesions destroying the wall of a major bronchus. Microscopically, 
several patterns are recognized. The oat cell type consists of round or elongated 
poorly cohesive cells slightly larger than lymphocytes. The tumor cells have 
dark clumped chromatin and little cytoplasm. Necrosis is usually present. The 
intermediate cell type of small cell carcinoma is composed of cells slightly 
larger than those of the oat cell type and with somewhat better intercellular 
cohesion and organization into lobules[13].  
CARCINOIDS 
 Bronchial carcinoids are tumors of low grade malignancy with 
neuroendocrine differentiation. The majority of carcinoids arise in central 
bronchi where they form a smooth  endobronchial polypoid growth. 
Microscopically carcinoids are formed of uniform cells with a fairly abundant 
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finely granular cytoplasm and oval, centrally located nuclei with clumped 
chromatin[14].  
MESENCHYMAL TUMORS 
 Mesenchymal tumors of the lung are rare. These tumors have the same  
histological features as their counterpart in the soft tissues. 
MIXED EPITHELIAL – MESENCHYMAL TUMORS 
 According to WHO classification, carcinosarcoma is defined as a 
malignant tumor with an admixture of carcinoma and sarcoma. 
LYMPHOMA 
 Primary pulmonary lymphoma accounts for less than 0.5% of all 
lymphomas. Most primary lymphomas of the lung originate from the mucosa 
associated lymphoid tissue (MALT) and present as slow growing solitary 
lesions. 
MESOTHELIOMA 
 Mesotheliomas are tumors of pleura. They are subdivided into epithelial, 
sarcomatoid and biphasic tumors. Epithelial tumors may be indistinguishable 
from adenocarcinoma. Sarcomatous tumors have usually features of 
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fibrosarcoma or malignant fibrous histiocytoma. Biphasic tumors resemble 
synovial sarcoma. 
MISCELLANEOUS RARE TUMORS AND TUMOR LIKE LESIONS 
 Rare tumors and tumor like lesions of the lung include pulmonary 
blastula, pulmonary endodermal tumor resembling fetal lung, primary 
malignant melanoma, malignant ependymoma, meningioma, malignant 
melanotic schwannoma, and many others. 
METASTATIC TUMORS 
 Lungs are commonly involved by metastatic tumors, which originate 
from any site. Both carcinomas and sarcomas metastasize to lungs. 
Histologically many of these tumors are indistinguishable from primary 
pulmonary neoplasms. 
FIBREOPTIC BRONCHOSCOPY 
 In the late 1890’s Gustav Killian used a rigid tube to remove an 
impacted piece of bone from the right mainstem bronchus of an awake 63 year 
old man. Twenty years later, Chevalier Jackson popularized extensive 
examination and therapeutic interventions using rigid bronchoscopy. Jackson 
developed a rigid bronchoscope with a small light at its tip to illuminate the 
airways. His techniques were very effective; however they required specialized 
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training, and only a few physicians obtained the skills required to safely 
perform the procedures. 
The advent of the flexible fibreoptic bronchoscope in 1970s 
revolutionized the field of brochoscopy.  It was first introduced by Ikeda in 
1967. Various models of fibreoptic bronchoscopes are produced by several 
manufacturers, and each model has particular advantages and limitations. 
These models differ in outer diameter from less than 4 mm to more than 6 mm 
and also in arc of bending from 60 to 180 degrees. Viewing angles vary from 
66 to 100 degrees, and side channel diameters range from1.2 to 3.2 mm. 
Ultrathin fibreoptic bronchoscopes (1.8 to 2.2 mm) are also available, but their 
usefulness is still under evaluation[15].   
INDICATIONS OF FLEXIBLE BRONCHOSCOPY 
• Examination of airway to the subsegmental level 
• Aspiration of secretions 
• Mucosal brushings 
• Biopsy of endobronchial lesions 
• Development of expandable airway stents 
• Removal of small foreign bodies 
• Transbronchial needle biopsy 
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PROCEDURE 
General considerations 
• Complete review of medical and surgical history of the patient 
• Identification of medical issues such as bleeding dyscrasias or 
significant allergy to an anesthetic agent  
• All recent radiographic studies should be reviewed 
• Patient must be informed about risks and benefits of the procedure 
Awake fibreoptic bronchoscopy  
 Oxygen is provided either via a nasal canula or by face mask with an 
opening to allow for the passage of bronchoscope. Monitoring should include 
pulse oximetry and heart at a minimum. Intravenous line must be started. 
Bronchoscopy carts are maintained. These carts are stocked with a flexible 
bronchoscope, a light source, suction tubing, bite blocks, oxygen masks, local 
anesthetics, pulse oximetry and emergency airway equipment. A standard adult 
bronchoscope with an external diameter of 5.9 mm used for these procedures. 
Adequate topical anesthesia is essential. 
Flexible bronchoscopy under general anesthesia 
 It is performed in operating room in conjunction with an 
anesthesiologist. Monitoring includes pulse oximetry, non – invasive blood 
pressure monitoring and three lead electrocardiogram monitoring. The 
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endotracheal tube used is of 8 mm in diameter. This tube allows ventilation via 
bronchoscope during use of a standard 5.9 mm diameter bronchoscope.   
Operation 
Awake fibreoptic bronchoscopy 
 The patient is placed in a bed and back elevated to 60 degrees. Pulse 
oximetry and heart rate monitoring is begun. Supplemental oxygen is provided 
by a face mask with a hole cut in it to allow passage of the bronchoscope. 
Topical anesthesia is provided. Once the oral pharynx, vocal cords and airway 
have been completely anesthetized, a bite block is placed in the mouth and the 
bronchoscope is introduced into the oral pharynx. The patient is asked to take 
deep breath opening the vocal cords and the bronchoscope is passed into the 
proximal trachea. The observer is oriented by noting the posterior longitudinal 
muscle along the membranous portion of the trachea. The carina is located and 
a systematic examination of the airway is carried out down to the subsegmental 
level. Samples are obtained from suspected lesions. 
Fibreoptic bronchoscopy under general anesthesia 
 The patient is brought to the operating room and general anesthesia is 
induced. Direct laryngoscopy is performed and an 8 mm endotracheal tube is 
placed. The endotracheal tube is connected to the ventilator through a 
bronchoscopy adapter. The surgeon stands at the head end of the table. Flexible 
bronchoscopy is carried out. Samples are collected[16].  
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Complications 
 Complications are low. Bleeding dyscrasias should be addressed prior to 
the procedure, especially if biopsy is planned. A high percentage of 
complications surrounding awake flexible bronchoscopy is related to 
preprocedural intravenous sedation. This can be avoided by proper application 
of local anesthesia. Significant hypoxia must be avoided[17]. 
Histopathological grading: 
Squamous cell carcinoma:  
 Grading of squamous cell carcinoma into well, moderately and poorly 
differentiated types will depend on the degree of squamous differentiation 
within the tumor such as the presence of intercellular bridges and 
keratinization. Well differentiated tumors are characterized by sheets of cells 
which adapt a pavement like architecture and contain ample eosinophilic 
cytoplasm, round to oval nuclei and prominent nucleoli. The cell borders are 
well defined and show well formed intercellular bridges. In the less 
differentiated tumor, the above features may be focally observed and the 
lesions are characterized by more pronounced cytologic atypia, increased 
mitotic activity and frequent areas of necrosis and hemorrhage. 
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Broder's Classification of Squamous cell carcinoma: 
1 Well differentiated            (Grade I) < 25% undifferentiated cells 
2 Moderately differentiated (Grade II) < 50% undifferentiated cells 
3 Poorly differentiated         (Grade III) <75% undifferentiated cells 
4 Anaplastic/pleomorphic    (Grade IV) >75% undifferentiated cells 
 
Adenocarcinoma:   
 Grading of adenocarcinoma into well, moderately and poorly 
differentiated tumors depend on the degree and extent of glandular 
differentiation. Well differentiated neoplasms are characterized by proliferation 
of well formed glands lined by atypical cells that infiltrate the surrounding 
stroma whereas poorly differentiated tumors grow as solid sheets of tumor cells 
with scant or poorly formed glandular structures and are recognized as 
adenocarcinomas on the basis of demonstration  of intra cellular mucin 
production. 
p63 
 p63 gene is structurally similar to p53 gene, consisting of 5’ region that 
codes for a protein moiety that activates transcription of same genes activated 
by p53, a central sequence coding for a DNA binding region, and a3’ sequence 
coding for an oligomerization – promoting region. 
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 The p63 gene codes for 6 protein isoforms based on alternate splicing 
and the existence of 2 promoters, one conventional, the other a biologically 
active internal promoter that generates truncated p63 proteins that fail to 
activate transcription and act as dominant negative blockers of p53 protein 
actions. 
 p63 has been postulated to have a critical role in maintaining the balance 
between basaloid stem cell commitments to undergo amniotic differentiation 
versus retention of a dividing undifferentiated stem cell phenotype. 
 To date p63 expression has been demonstrated in basal layers of 
squamous epithelia, urothelium, basal layers of prostate gland epithelia, 
myoepithelial cells of, submucosal gland epithelia and in the basal reserve cells 
of ciliated bronchial epithelia. 
 p63 is hypothesized to play an important role in maintaining the 
epidermal stem cell population. Immunohistochemical analyses show p63 
protein localization and expression in basal/progenitor cells of several 
epithelial tissues such as epidermis mammary glands, prostate and urogenital 
tract. p63 expression is lost as these cells migrate from the basal layer and 
become terminally differentiated cells. 
 As with Pierre P. Massion et.al, in invasive carcinomas, p63 staining 
was scored 0–4 based on intensity[19]. In preinvasive lesions, p63 was scored 
based as follows:  
  22
 
S. No Score Characterized by 
1 0 No staining 
2 1 Basal layer staining 
3 2 Basal and parabasal layer staining 
4 3 Full thickness staining 
5 4 Invasion of basement membrane 
 
 Charles J. Di como et al, (feb, 2002) in their study examined the 
expression pattern of p63 in human normal and tumor tissues by 
immunohistochemistry using a monoclonal antibody that recognizes all p63 
spilce variants, and by reverse transcription-PCR using isoform-specific 
primers.  They observed that the expression was restricted to epithelial cells of 
stratified epithelia, such as skin, esophagus, exocervix, tonsil, and bladder, and 
to certain subpopulations of basal cells in glandular structures of prostate and 
breast, as well as in bronchi. They found that p63 is expressed predominantly 
in basal cell and squamous cell carcinomas, as well as transitional cell 
carcinomas, but not in adenocarcinomas, including those of breast and prostate. 
Thymomas and a subset of Non-hodgkin’lymphomas were also found to 
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express p63. p63 was not found to be expressed in endocrine tumors, germ cell 
neoplasms, or melanomas. Soft tissue sarcomas were found to have 
undetectable p63 levels[18]. 
 Pierre P. Massion et al, (nov, 2003) analysed p63 gene copy number 
by fluorescence in situ hybridization and expression by immunohistochemistry 
in tissue microarrays of 217 non-small cell lung carcinomas and correlated 
them with survival. They also analysed  p63 copy number and protein 
expression in 41 preinvasive squamous lesions. The p63 genomic sequence was 
amplified in 88% of squamous carcinomas, in 42% of large cell carcinomas, 
and in 11% of adenocarcinomas of the lung. They also found  p63 genomic 
amplification and protein staining intensity associated with better survival. 
They found a significant increase in p63 in preinvasive lesions graded severe 
dysplasia or higher. They demonstrated that there is early and frequent genomic 
amplification of p63 in the development of squamous cell carcinoma of the 
lung and that patients with non small cell lung carcinoma showing 
amplification and over expression of p 63 have prolonged survival. These 
observations suggest that p63 genomic amplification has an early role in lung 
tumorigenesis[19]. 
 Claudia Auw-Haedrich et al, (2006) investigated the expression of p63 
in conjunctival intraepithelial neoplasia of different grades and conjunctival 
squamous cell carcinoma and its correlation to the proliferation marker MIB-1. 
They took seventeen conjunctival specimens excised with a suspicion of either 
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conjunctival intraepithelial neoplasia or squamous cell carcinoma and 
diagnosed histologically as: squamous cell carcinomas of conjunctiva, CIN 
grade 1, CIN grade 2, CIN grade 3, normal conjunctiva with no dysplasia. 
Sixteen microscopically normal post mortem conjunctival specimens were also 
also taken. All the specimens were stained immunohistochemically with 
antibodies against p63 and MIB-1. atleast 500 cells per specimen were counted 
and the percentage of positively stained cells of each antibody was calculated. 
Their results showed that a mean of 80% of the dysplastic cells from the CIN 
specimens stained positively with antibodies against p63, especially in the 
lower two thirds of the epithelium, statistically significantly more when 
compared with the normal specimens. They did not find a correlation between 
the percentage of p63 positive cells and the differentiation grade of the 
malignant specimens. MIB-1 positivity was seen in 0-1% of cells in the normal 
postmortem controls, 3-30% cells in the basal and occasionally in the middle 
layer of the CIN specimens and 16-61% in the carcinoma specimens. They 
concluded that p63 was preferentially expressed in the immature dysplastic 
epithelial cells. Its staining does not correlate with MIB-1 expression and 
therefore does not appear to be linked to cell proliferation[20]. 
 P Taniere et al, (2001), studied the amplication of p63 in squamous cell 
carcinoma of esophagus from a low incidence area in Western Europe and 
compared with p63 amplification in areas with high incidence of squamous cell 
carcinomas of esophagus. Results indicated that squamous cell carcinomas of 
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esophagus from areas of high and low incidence present with similar pattern of 
p63 amplification but differ by the type of TP53 mutations[21]. 
 Hina A Sheikh et al, (2004) studied, 33 cases of adenocarcinoma and 
43 cases of benign lungs with fibrosis and metaplasia for nuclear p63 
expression by immunohistochemistry. Five additional cases each of atypical 
adenomatous hyperplasia and adenosquamous carcinoma and three cases of 
squamous cell carcinomas were also stained. The diagnostic categories of 
benign lung conditions were usual interstitial pneumonia, parenchymal scar, 
cryptogenic organizing pneumonia and diffuse alveolar damage. In neoplastic 
cases, p63 positivity was calculated as percentage of all tumor cells examined. 
In areas of normal lung, p63 decorated the reserve cells of large and small 
airways and occasional cells of the distal lobular unit. In fibrotic reactive 
processes, an interrupted but distinct pattern of nuclear staining was present in 
all cases, with staining of basal cells of the airways as well as bronchiolar- and 
squamous-metaplastic epithelium (43/43, 100%). p63 immunoreactivity was 
less uniform in areas of acute lung injury within these cases. One 
adenocarcinoma and two cases of atypical adenomatous hyperplasia showed 
strong immunoreactivity (>80%), while three adenocarcinomas highlighted 
only rare tumor nuclei (<5% of tumor cells). Morphologic areas where p63 
immunostaining was not helpful included the junction of normal lung and 
lepidic growth of adenocarcinoma, and retrograde spread of adenocarcinoma 
into small airways. Their results highlight the differential expression of p63 
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across various bronchioloalveolar lesions. They concluded that p63 may be 
helpful in distinguishing reactive from neoplastic glandular proliferations in the 
lung[22]. 
 Hu NH et al (2004), investigated the expression of p63 in a broad 
spectrum of histologic types of lung tumors. A total of 441 cases of primary 
lung tumors with follow-up data were identified, and the paraffin-embedded 
tissue blocks were used to construct a duplicate core tissue microarray. After 
review of the tissue cores, 408 cases, consisting of 123 squamous cell 
carcinomas, 93 adenocarcinomas, 68 large cell carcinomas, 68 classic 
carcinoids, 31 atypical carcinoids, 11 large cell neuroendocrine carcinomas, 
and 14 small cell carcinomas, were adequate for analysis. 
Immunohistochemistry was performed to detect the expression of p63, using 
different staining protocols.  p53 expression was also studied with 
immunohistochemistry. A large proportion of squamous cell carcinomas 
expressed p63 (96.9%), most showing strong positive nuclear 
immunoreactivity. Expression in other non small cell lung cancers was also 
present. 30% of adenocarcinomas and 37% of large cell carcinomas showed 
p63 expression. In the neuroendocrine tumors, an increasing proportion of 
tumors stained for p63 as tumor grade increased; 1.9% of classic carcinoids, 
30.8% of atypical carcinoids, 50% of large cell neuroendocrine carcinomas, 
and 76.9% of small cell carcinomas were positive. Approximately half of the 
positively staining neuroendocrine cases showed strong staining. Expression of 
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p63 was of prognostic significance in neuroendocrine tumors, with higher-
grade tumors more likely to express p63. Correlation between p63 and p53 
expression was not observed  in non small cell lung cancers; however, a 
significant correlation between the 2 markers was found in neuroendocrine 
tumors. p63 staining was repeated with a different staining protocol, yielding 
similar results overall but a lower percentage of positive cases (34.2% vs. 
48.4% of tumors positive). They  concluded that p63 expression is consistently 
expressed in squamous cell carcinoma in the lung, but is also expressed in a 
subset of adenocarcinomas and large cell carcinomas. Pulmonary 
neuroendocrine tumors also show p63 staining in some instances, particularly 
in higher-grade tumors, and the majority of small cell carcinomas are  
p63-positive[23]. 
 Jorda M et al, (2005) studied the value of p63 immunocytochemical 
analysis in classification of nonsmall cell carcinomas into squamous and non 
squamous subtypes. They considered 51 consecutive pulmonary specimens (16 
fine needle aspiration samples, 15 washes, 12 brushes, and 8 lavages) with the 
diagnosis of nonsmall cell lung carcinoma (9 carcinomas with squamous 
differentiation and 42 carcinomas without squamous differentiation). 
Histologically, they all proved to be nonsmall cell carcinomas, 26 with 
squamous differentiation and 25 without squamous differentiation. p63 
immunocytochemical stain was performed. 23 (88 %) of the 26 histologically 
proven squamous cell carcinomas were positive for p63 on cytologic smears. 
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By using p63 immunocytochemistry, they detected 14 carcinomas with 
squamous differentiation not identified by cytomorphology. Smears from all 
histologically proven carcinomas with squamous differentiation were positive 
for p63. Sensitivity of cytology for the detection of non small cell carcinoma of 
lung with squamous differentiation increased from 35% to 88% using p63 
immunocytochemistry. The squamous component in 4 carcinomas was 
detected only in cytologic and not in corresponding histologic samples when 
subsequent p63 immunostaining was performed. They concluded that p63 is a 
useful marker for the detection of non small cell carcinomas of lung with 
squamous differentiation when used in cytologic pulmonary samples. p63 
immunocytochemistry significantly increases the sensitivity for the 
identification of lung neoplasms with squamous differentiation from 35% to 
88%. Therefore, p63 immunocytochemistry may be used in pulmonary 
cytologic samples of non small cell carcinomas to identify squamous 
differentiation and to improve therapeutic selection of patients with lung 
cancer[24]. 
 Viktor Shtilbans Ph.D, et al, (2005) attempted to detect p63 in 
destained slides from a spectrum of pulmonary malignancies (small biopsies 
and cytological cell blocks). 60 cases of cytologically diagnosed malignancies 
in bronchoscopically or fine-needle aspiration-obtained specimens were 
immunostained with p63. Normal ciliated and goblet cells were p63 negative, 
but reserve cells were p63 positive. All cases of squamous-cell carcinoma were 
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positive for p63. Of 10 tumor samples originally diagnosed as Squamous cell 
carcinomas, only 6 samples were p63 negative and 4 samples exhibited positive 
staining. However, proper interpretation of the immunohistochemical staining 
pattern and careful scrutiny of the cytological features and biopsy specimens in 
three of four cases led them to reclassify three cases into poorly differentiated 
squamous cell carcinomas. All adenocarcinomas, large-cell carcinomas, and 
metastatic adenocarcinomas were p63 negative. Positive staining was seen in 
9/16 tumors designated as non-squamous cell carcinomas; these tumors were 
not classified further into distinct histological categories[25]. 
 Esther conde et al (2010), in their study confirmed a previous 
microarray study, in which they found that one of the top differentially 
expressed genes between adenocarcinomas and squamous cell carcinomas is 
p63. They analysed the value of P63 immunohistochemistry  in reducing the 
number of large cell carcinoma  diagnoses in surgical specimens. They 
investigated the potential of P63 IHC to minimize the proportion of carcinoma 
NOS (not otherwise specified) in a prospective series of small tumor samples. 
They studied p63 staining of 33 adenocarcinomas, 99 squamous cell 
carcinomas, 20 large cell carcinomas and 32 carcinoma NOS. They proved that 
P63 IHC was differentially expressed in Squamous Cell Carcinomas when 
compared to Adenocarcinomas[26]. 
 Thus from the above studies it is understood that p63, a recently 
discovered member of the p53 family has been shown to be important in the 
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development of epithelial tissues. It does not correlate with the expression of 
proliferation markers and thus it is not a cell proliferation marker. p63 plays a 
role in squamous cell carcinomas of the lung, head and neck, and cervix, and 
its expression is increased in these tumors. p63 plays a major role in lung 
tumorigenesis. It is used to identify lung tumors with squamous differentiation. 
It can also be used in pulmonary cytologic samples of nonsmall cell carcinomas 
to identify squamous differentiation. 
 In this study,  the expression of p63 in varying grades and histologic 
types of lung malignancies in fibreoptic lung biopsy specimens at Department 
of Pathology, Stanley Medical College has been studied.  p63 expression in 
various lung carcinomas in our population is then correlated with the above 
studies. 
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IMMUNOHISTOCHEMISTRY 
 Immunohistochemistry involves two disciplines – immunology and 
histology. Immunohistochemistry is used to determine expression of particular 
antigen and its microanatomic location in the tissue. IHC uses antibodies to 
distinguish the antigenic differences between the cells. These differences can 
specifically identify the lineage of cell population and define biologically 
distinct populations of cells within the same lineage. 
 Immunohistochemistry started in 1940 when Coons developed an 
immunofluorescence technique to detect corresponding antigen in frozen 
sections. 
 Taylor and colleagues in 1974 showed it was possible to demonstrate 
antigens in routinely processed tissues. Antigen retrieval technique was 
introduced by Shi and associates in 1991. Antigen retrieval technique is a 
simple method that involves heating paraffin processed sections at high 
temperature before IHC staining. 
 The use of antibody in IHC depends on the sensitivity and specificity of 
the antigen – antibody reaction and the Hybridoma technique provides limitless 
source of highly specific antibodies. 
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Blocking non – specific background staining 
 Background staining is due to either non specific binding or presence of 
endogenous enzymes. Non specific binding with polyclonal primary antibody 
is minimized by pre incubating sections with serum from same species on 
optimal working dilution. 
 Endogenous enzymes such as peroxidase seen in normal and neoplastic 
tissues is abolished by peroxidase blocking or by using alternate systems such 
as immunogold technique. 
 Methods suggested to overcome endogenous activity include incubation 
in methanol containing 0.5% hydrogen peroxide for 10 minutes at room 
temperature (almost complete abolition of endogenous peroxidase activity). 
Endogenous alkaline phosphatase is blocked by addition of 0.1 M 
concentration of levamisole to the enzyme substrate solution. 
Detection systems 
 Antibodies are labeled or flagged by some method to permit 
visualization – these include fluorescent substances, enzymes forming colored 
reaction with suitable substrate (light microscopy) or heavy metals (electron 
microscopy). 
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Methods of IHC  
Direct labeling method 
 Antibody is attached with a label by chemical means and directly 
applied to tissue sections. It is a rapid and easy procedure and carries the 
disadvantage of multiple antigens which require separate incubation with 
respective antibodies. 
Indirect labeling method 
 Enzymes  are labeled with the secondary antibody, which is produced 
against primary antibody. This method is more sensitive and easy to handle. 
The advantages also include increased versality, higher working dilution of 
primary antibody, secondary antibodies against primary antibodies of different 
species and easy to prepare. 
Avidin biotin techniques 
 High affinity binding between biotin and avidin is used in this 
procedure. Biotin is chemically linked to primary antibody and avidin is 
conjugated chemically to enzyme. The avidin binds to biotinylated antibody 
thus localizing the peroxidase moiety at the site of antigen.  
 Disadvantages of this technique is that the endogenous biotin produces 
non specific background staining.  
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Avidin biotin conjugate procedure 
 In this technique primary antibody is added followed by biotinylated 
secondary antibody and next by preformed complexes of avidin and biotin 
horse raddish peroxidase conjugate. This is a more sensitive method. 
Biotin streptavidin system 
 Streptavidin is used in place of avidin. Streptavidin complexes are more 
stable. 
Immunogold silver staining technique 
 This is used in ultrastuctural immunolocalisation. Gold particles are 
enhanced by the addition of several layers of metallic silver. The fine silver 
deposits in the background create confusion when small amounts of antigen are 
identified.  
Polymeric method 
 This technique permits binding of large number of enzyme molecules to 
a secondary antibody via the dextran backbone. Advantages of this technique 
are increased sensitivity, minimized non specific background staining and a 
reduction in the total number of assay steps.  
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Tissue fixation, processing and antigen retrieval techniques 
 Tissues for IHC undergo fixation, dehydration and paraffin embedding.  
Fixation 
 This is a critical step as the preservation of morphology is essential for 
interpretation of IHC. 10% buffered neutral formalin is commonly used 
because of the following advantages. 
1. Good morphological preservation 
2. Cheap 
3. Sterilizes tissues  
4. Carbohydrate antigens are better preserved. 
 
 The disadvantage of masking of antigens during fixation can be 
overcome by antigen retrieval techniques. 
Antigen retrieval 
 This procedure involves unmasking of the antigens. Following 
techniques can be used. 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval  
3. Microwave and trypsin antigen retrieval technique 
4. Pressure cooker antigen retrieval 
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MATERIALS AND METHODS 
Source of the data 
 A total of 105 fibreoptic lung biopsy specimens were received in the 
Department of Pathology, Stanley medical college from Government Hospital 
of Thoracic Medicine, Tambaram Sanatorium during the year July 2008 to 
September 2010. 
Study design & Plan 
 Longitudinal prospective and retrospective study.  
 The patients who were included in this study were screened for 
predetermined inclusion and exclusion criteria. Selected patients underwent 
through consent protocols. Brief clinical history and examination was done 
with predetermined proforma.  
Inclusion Criteria 
 All patients undergoing fibreoptic endoscopic biopsies, irrespective of 
age and sex were included for the study 
Exclusion Criteria 
 Patients with inadequate biopsy material were excluded from the study. 
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Methods of data collection 
 Out of 105 cases adequate material was obtained in about 96 cases. 
Clinical history, radiological and necessary hematological findings were 
tabulated.  
 The tissues obtained by FOB were processed and sections were cut at  
5 microns. Haematoxylin and eosin staining of the sections was done and 
histopathological diagnosis was made. Necessary microphotographs were 
taken. 
 The various premalignant and malignant lesions were graded 
histopathologically. Immunostaining of the p63 was studied in all neoplastic 
lesions.  Percentage of p63 staining correlated with histological grade. Results 
were tabulated and conclusion was drawn.  
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Method of tissue preparation for IHC 
 10% buffered formalin was used for fixing the specimens, the tissues 
were processed in various grades of alcohol and xylol using automated 
histokinette. Paraffin blocks were prepared and sections of 5 microns thickness 
were cut in semiautomatic microtome using disposable blades and stained with 
hematoxylin and eosin. 
 Sections for immunohistochemistry were also cut in semiautomatic 
microtome using disposable blades. Slides coated with chrome alum were used. 
Sections were subjected to antigen retrieval using microwave technique using 
TRIS EDTA (pH 9.2) buffer solution and then treated by HPR (horse raddish 
peroxidase) polymer technique. 
HPR polymer technique 
The coated slides were taken through the following stages 
1. Treatment with peroxidase block – for inhibiting endogenous 
peroxidases in the tissue for 20 minutes 
2. Wash in TRIS buffer for 5 minutes 
3. Application of power block – blocks non specific antigen antibody 
reaction – 20 minutes 
4. Blot dry the excess power block 
5. Application of primary antibody for 60 minutes 
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6. Wash in TRIS buffer for 5 minutes thrice 
7. Application of super enhancer for 30 minutes which enhances the final 
reaction product by increasing the sensitivity of antigen antibody 
reaction 
8. Application of SS label – secondary antibody from goat with the tagged 
horse radish peroxidase enzyme for 30 minutes 
9. Wash thrice in TRIS buffer 
10. Application of DAB (diamino benzidine) chromogen for 5 minutes – 
this is cleaved by the enzyme to give the coloured product at the antigen 
sites 
11. Wash in distilled water for 5 minutes 
12. The slides are counterstained with hematoxylin 
13. Air dried and mounted with DPX (distrene dibutyle pthalide in xylol) 
 p63 nuclear staining pattern and staining intensity ranged from strong to 
moderate to weak. Staining was focal rather than extensive and confluent. 
Extent of staining varied from multiple positive foci to scattered or rare foci. 
METHODS OF SCORING 
 Included measurements of the intensity of staining or percentage of 
positive cells or a combination of the two.  
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SCORE FOR INTENSITY OF STAINING OF p63 
 0 – no staining 
 1 – weak staining 
 2 – moderate staining 
 3 – strong staining 
 
 This would give a maximum score of 300 if 100 percent of tumor cells 
show strong positivity. 
SCORE FOR PROPORTION OF POSITIVE CELLS 
 0 – less than 5% positive nuclei 
 1 – 5 to 25% positive nuclei 
 2 – 26 to 75% positive nuclei 
3 – over 75% positive nuclei 
 
PERCENTAGE METHOD 
 Positivity of cells was defined regardless of staining intensity. More 
than 10% of positive cells represented the cut off between negativity and 
positivity. 
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OBSERVATION AND RESULTS 
 A total of 96 cases were studied. Morphology showed the following 
results. 
NORMAL         45  
NON NEOPLASTIC LESIONS      22 
Non specific inflammation       8 
Chronic inflammation       9  
Granulomatous lesion       3 
Other infections (candidiasis, aspergillosis)    2 
PRE NEOPLASTIC LESIONS      6 
Mild dysplasia  (fig. 1,2)                  2 
Moderate dysplasia(fig. 3,4)      3 
Severe dysplasia(fig. 5,6)       1 
NEOPLASTIC LESIONS      23 
Squamous cell carcinoma(fig. 7,8,9,10)     12 
Adenocarcinoma(fig. 11,12)      8 
Bronchioloalveolar carcinoma      1 
(mucinous type) 
Bronchioloalveolar carcinoma      1 
(non mucinous type) 
Large cell carcinoma       1 
 
  43
AGE AND SEX DISTRIBUTION OF PATIENTS UNDERGOING 
FIBREOPTIC LUNG BIOPSY 
TABLE NO 1 
Age 
Non 
Malignant 
Pre 
Malignant Malignant Total 
  M F T M F T M F T M F T 
21 TO 30 4 4 8 0 0 0 0 0 0 4 4 8
31 TO 40 7 3 10 0 0 0 2 0 2 9 3 12
41 TO 50 19 1 20 2 0 2 6 1 7 27 2 29
51 TO 60 20 1 21 1 0 1 5 0 5 26 1 27
61 TO 70 8 5 13 2 0 2 6 1 7 16 6 22
71 TO 80 2 2 4 1 0 1 0 1 1 3 3 6
81 TO 90 0 0 0 0 0 0 1 0 1 1 0 1
TOTAL 60 16 76 6 0 6 20 3 23 86 19 105
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AGE AND SEX DISTRIBUTION OF LUNG MALIGNANCIES 
TABLE NO 2 
Age 
Squamous 
Cell 
Carcinoma 
Adeno 
Carcinoma Others Total 
  M F T M F T M F T M F T 
21 TO 30 0 0 0 0 0 0 0 0 0 0 0 0
31 TO 40 2 0 2 0 0 0 0 0 0 2 0 2
41 TO 50 3 0 3 2 0 2 1 1 2 6 1 7
51 TO 60 2 0 2 2 0 2 1 0 1 5 0 5
61 TO 70 4 0 4 2 1 3 0 0 0 6 1 7
71 TO 80 0 0 0 0 1 1 0 0 0 0 1 1
81 TO 90 1 0 1 0 0 0 0 0 0 1 0 1
TOTAL 12 0 12 6 2 8 2 1 3 20 3 23
 
 Age range of patients undergoing fibreoptic lung biopsies was from 21 
to 85. The age range of squamous cell carcinoma was from 35 to 85 and 
adenocarcinoma was from 45 to 75. 
 Both squamous and adenocarcinomas occurred in males predominantly. 
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CLINICAL PRESENTATION OF LUNG MALIGNANCIES 
SQUAMOUS CELL CARCINOMA 
TABLE NO  3 
 
CLINICAL PRESENTATION 
NO OF 
CASES % 
COUGH 7 58.33% 
HEMOPTYSIS 4 33.33% 
BREATHLESSNESS 10 83.33% 
LOSS OF WEIGHT 11 91.67% 
CHEST PAIN 6 50% 
 
ADENOCARCINOMA 
TABLE NO 4 
CLINICAL PRESENTATION 
NO OF 
CASES % 
COUGH 6 75% 
HEMOPTYSIS 0 0% 
BREATHLESSNESS 5 62.50% 
LOSS OF WEIGHT 8 100% 
CHEST PAIN 3 37.50% 
  
 Cough, breathlessness and weight loss were the most common clinical 
presentation of both squamous and adenocarcinoma. 
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ASSOCIATION OF MALIGNANCIES WITH SMOKING 
SMOKING ASSOCIATION IN NON MALIGNANT AND MALIGNANT 
LESIONS 
TABLE NO 5 
 
H/O 
SMOKING
NO H/O 
SMOKING TOTAL 
MALIGNANT 
LESIONS 17 12 29 
NON MALIGNANT 
LESIONS 42 34 76 
TOTAL 57 48   
 
Yates corrected chi square – 0.0081; p value – 0.9282(not significant)  
SMOKING ASSOCIATION IN SQUAMOUS AND NON SQUAMOUS 
MALIGNANCIES 
TABLE NO 6 
 
H/O 
SMOKING
NO H/O 
SMOKING TOTAL 
SQUAMOUS CELL 
CARCINOMAS 9 3 12 
NONSQUAMOUS 
CELL CARCINOMAS 3 8 11 
TOTAL 12 11   
 
Yates corrected chi square – 3.5010; p value – 0.0613(not significant). 
 Squamous cell carcinomas were most commonly associated with history 
of smoking which is statistically insignificant probably due to reduced sample 
size. 
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IMAGING FINDINGS 
SQUAMOUS CELL CARCINOMA 
TABLE NO 7 
 
XRAY FINDINGS NO OF CASES % 
HILAR MASS 5 41.65% 
CONSOLIDATION 3 25% 
OPACITY 1 8.33% 
CAVITY 1 8.33% 
RIB METASTASIS  1 8.33% 
NORMAL 1 8.33% 
 
ADENOCARCINOMA 
TABLE NO 8 
XRAY FINDINGS NO OF CASES % 
OPACITY 5 62.50% 
CONSOLIDATION 1 12.50% 
HILAR 
PROMINANCE 1 12.50% 
PLEURAL EFFUSION 1 12.50% 
 
 Most common x ray finding of squamous cell carcinomas was found to 
be hilar mass. Other less common findings are consolidation, opacity and 
cavity formation. Most common x ray finding of adenocarcinomas was found 
to be opacity. Other less common findings are consolidation, hilar prominence, 
pleural effusion. 
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FIBREOPTIC BRONCHOSCOPIC FINDINGS 
SQUAMOUS CELL CARCINOMA 
TABLE NO 9 
 
FOB FINDINGS NO OF CASES % 
GROWTH 10 83.33% 
UNHEALTHY 
MUCOSA 1 8.33% 
NECROTIC 
MATERIAL 1 8.33% 
    
ADENOCARCINOMA 
TABLE NO 10 
FOB FINDINGS NO OF CASES % 
GROWTH 6 75% 
NARROWING OF 
BRONCHUS 2 25% 
 
 Most of the carcinomas (squamous and adeno) presented with 
endobronchial growth at fibreoptic bronchoscopy. 
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p63 EXPRESSION IN MALIGNANCIES 
TABLE NO 11 
S.NO 
BIOPSY 
NO HISTOLOGICAL TYPE 
p63 
SCORE 
1 1157/09 SEVERE DYSPLASIA 3 
2 1367/09 MODERATE DYSPLASIA 2 
3 1368/09 
POORLY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 0 
4 1465/09 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 3 
5 5676/09 ADENOCARCINOMA 0 
6 5677/09 ADENOCARCINOMA 0 
7 2429/09 ADENOCARCINOMA 0 
8 2702/09 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 2 
9 2860/09 LARGE CELL CARCINOMA 0 
10 2861/09 ADENOCARCINOMA 0 
11 3430/09 
BRONCHIOLOALVEOLAR 
NONMUCINOUS CARCINOMA 0 
12 4025/09 ADENOCARCINOMA 0 
13 4321/09 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 3 
14 4454/09 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 1 
15 4455/09 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 3 
16 4603/09 MILD DYSPLASIA 1 
17 4936/09 
POORLY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 1 
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S.NO 
BIOPSY 
NO HISTOLOGICAL TYPE 
p63 
SCORE 
18 5033/09 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 1 
19 5138/09 MILD DYSPLASIA 1 
20 5515/09 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 1 
21 405/10 
BRONCHIOLOALVEOLAR MUCINOUS 
CARCINOMA 0 
22 624/10 MODERATE DYSPLASIA 2 
23 625/10 MODERATE DYSPLASIA 2 
24 791/10 ADENOCARCINOMA 0 
25 1039/10 ADENOCARCINOMA 0 
26 2030/10 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 2 
27 2068/10 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 3 
28 1041/10 
MODERATELY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 1 
29 2027/10 ADENOCARCINOMA 0 
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p63 EXPRESSION IN SQUAMOUS AND NON SQUAMOUS 
MALIGNANCIES 
TABLE NO 12 
 
p63 EXPRESSION POSITIVE NEGATIVE TOTAL 
SQUAMOUS CELL 
CARCINOMAS 11 1 12 
NON SQUAMOUS 
CELL CARCINOMAS 0 11 11 
TOTAL 11 12 23 
 
Yates corrected chi-Square 12.5484; p value – 0.0004(significant) 
 Most of the preinvasive and invasive lesions with squamous 
differentiation showed nuclear positivity for p63(fig.13 to 18). Other 
carcinomas were negative for p63(fig.19) 
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p63 SCORE IN PRE INVASIVE LESIONS 
TABLE NO 13 
 
p63 SCORE 0 1 2 3 TOTAL
MILD DYSPLASIA 0 2 0 0 2
MODERATE DYSPLASIA 0 0 3 0 3
SEVERE DYSPLASIA 0 0 0 1 1
TOTAL 0 2 3 1 6
 
p63 score showed progressive increase through mild to severe dysplasia. p 
value cannot be determined due to the smaller sample size. 
p63 SCORE IN SQUAMOUS CELL CARCINOMAS 
TABLE NO 14 
p63SCORE 0 1 2 3 TOTAL 
MODERATELY 
DIFFERENTIATED SQUAMOUS 
CELL CARCINOMA 0 3 2 5 10 
POORLY DIFFERENTIATED 
SQUAMOUS CELL CARCINOMA 1 1 0 0 2 
TOTAL 1 4 2 5 12 
 
 p63 score ranged from 0 to 3 in different histologic grades of squamous cell 
carcinomas. p value cannot be determined due to the smaller sample size. 
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DISCUSSION 
 Lung cancer is the most common fatal malignancy in men and women. 
Lung cancer has a peak incidence in the group 50 to 70 years of age[27] 
whereas in this study, the age range of lung malignancies was found to be 35 to 
85 and peak incidence was around 40 to 70 years of age. Lung cancer is more 
common in males than in females. In this study also it is more common in 
males. This may be due to less use of medical services by females in our 
population[28].  
 Local and systemic symptoms of most lung cancers are related to mass 
effect of the tumor. Local symptoms include cough, hemoptysis, dyspnoea and 
chest pain.  Systemic symptoms include weight loss, cachexia and pain 
attributable to metastases[29]. In concordance with literature, the most 
common clinical presentations in this study were found to be cough, 
breathlessness and weight loss. 
 All cell types of lung cancer are associated with smoking. The strongest 
associations are with small cell and squamous cell carcinomas[31]. Similarly, 
in this study, squamous cell carcinomas were found to be most commonly 
associated with history of smoking. 
 Performing a chest radiograph is the first step if a patient reports with 
symptoms that may suggest lung cancer. This may reveal an obvious mass, 
widening of the mediastinum (suggestive of spread to lymph nodes there), 
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atelectasis (collapse), consolidation (pneumonia), opacity, cavity, pleural 
effusion[30]. Accordingly, in this study, the most common x ray findings were 
found to be hilar mass, opacity and consolidation. 
 Tissue needs to be obtained to confirm the diagnosis of lung cancer. 
Flexible bronchoscopy  is an  invasive, nonsurgical approach used to obtain 
tissue. Flexible bronchoscopy has a high diagnostic yield for endoscopically 
visible lesions. Most common findings at fibreoptic bronchoscopy were 
growth, purulent secretions, inflamed mucosa and necrotic material[32]. In this 
study also, the most common findings at fibreoptic bronchoscopy were growth, 
unhealthy mucosa, necrotic material and narrowing of bronchus. 
 The incidence of lung cancer seems to be on increase in Asia and many 
other parts of the world and currently death caused by lung cancer is the 
leading cause of neoplasia related mortality world wide[33]. This may be due 
to lack of early detection strategies in diagnosis of lung tumors. Genomic 
abnormalities may play a major role in malignant transformation and tumor 
progression[34]. 
 p63 is a transcription factor that transactivates p53 target genes [35] and 
induces apoptosis when expressed in cells [36]. Although p63 was recently 
discovered, it is the most ancient member of the p53 family [37]. 
 p63 genomic sequence is found in chromosome 3q27. Chromosome 
3q26-ter amplification, which includes the p63 gene locus, is one of the most 
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prevalent genomic abnormalities in solid tumors and is likely to play a critical 
role in tumorigenesis. Amplification of chromosome 3q has been described in 
squamous epithelial transformation from the lung [39], head and neck [40,41], 
esophagus [42], bladder [43], cervix [44,45], and stomach [46]. It is 
demonstrated that the presence of 3q amplification alone allows the distinction 
between squamous and adenocarcinoma in more than 75% of cases [47]. 
 p63 functions as a potent transcriptional repressor and dissociates from 
promoter binding sites of key growth inhibitory genes during normal human 
keratinocyte differentiation[38]. Thus,  p63 gene overexpression may have 
important implications in lung tumorigenesis. 
 In this study, fibre optic lung biopsies received at the Department of 
Pathology, Stanley Medical College  were analysed and expression of p63 was 
studied in varying histologic types and grades of lung carcinomas.  
 A total of 105 specimens were received during the period of July 2008 
to September 2010. 96 samples had adequate material and were included in the 
study. 
 29 cases were diagnosed to be preinvasive and invasive lesions. 
 There were 6 pre invasive lesions (mild, moderate and severe dyplasias),  
12 squamous cell carcinomas, 8 adenocarcinomas, 1 in each of 
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bronchioloalveolar carcinoma mucinous and non mucinous type and 1 large 
cell carcinoma. P63 immunoprotein status was studied in these cases. 
 All invasive and preinvasive lesions of squamous differentiation showed 
nuclear positivity for p63 immunoprotein. Scoring was done according to the 
percentage of cells which showed p63 positivity in each lesion. 
 p63 score showed progressive increase through mild to severe dysplasia. 
This is in accordance with the data previously reported by Pelosi et al. [48] and 
Sniezek et al. [49] in a small series of head and neck and lung tumors. Also, 
Pierre P. Massion et al.[50], in his study showed that, in preinvasive tumors, 
p63 staining involved not only the basal but also the supra-basal layers and 
followed a pattern consistent with severity of histological grade. In invasive 
tumors, p63 was seen throughout the whole sheet of invasive tumor. It is 
apparent that p63 expression increases progressively from preinvasive to 
invasive lesions during the transformation of squamous epithelia. 
 91.6% (11/12) of squamous cell carcinomas showed p63 expression. 
p63 score ranged from 0 to 3 in different histologic grades of squamous cell 
carcinoma. It was found that p63 overexpression were extremely prevalent in 
squamous cell carcinomas. This is in accordance with a recent study, in which 
Pelosi et al. [48] examined the percentage of p63-positive cells by IHC, yet did 
not find an association between p63 expression and survival. But the majority 
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of cancer cells (80%) stained for p63 in squamous cell carcinomas. He found 
p63 immunoreactivity in 92.4% (109/118) of squamous cell carcinomas. 
 Poorly differentiated tumors showed decreased expression of p63 
immunostaining. This may be due to the fact that as the normal cell transforms 
to dysplastic cells, they develop p63 genomic amplification. As the neoplastic 
cells become less differentiated, p63 expression is decreased. Thus, p63 may be 
an important marker of cell differentiation and confer survival advantage[50]. 
 All adenocarcinomas showed no expression of p63. This is in 
accordance with Pierre P. Massion et al[50], who showed that p63 gene 
amplification occurs in the majority of squamous cell carcinomas, rarely in 
adenocarcinomas. Also, Charles J. Di Como et al[18], in his study showed that 
p63 expressed itself predominantly in basal cell and squamous cell carcinomas, 
as well as transitional cell carcinomas, but not in adenocarcinomas. Thus p63 
immunostaining can be used to distinguish between squamous and non 
squamous carcinomas. However, due to smaller sample size, the results 
observed in this study are inconclusive. Further studies involving larger sample 
size are necessary to confirm the association between the degree of squamous 
differentiation and p63 grading. 
 As p63 gene is located in chromosome 3, genes in the chromosome 3q 
amplicon may open a window for identification of potential targets for 
molecular intervention in preinvasive and invasive lung cancer. P63 plays a 
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critical role in early development of squamous cell carcinoma and thus p63 
amplification may prove to be an excellent biological marker of squamous cell 
tumor progression. 
 
 
 
 
 
 
 
 
 
 
  59
SUMMARY AND CONCLUSION 
 96 adequate samples of fibreoptic lung biopsy specimens received 
during the period between July 2008 to September 2010 were taken for the 
study. Demographic and risk factor analysis of the cases were done. 
Histopathological examination of all the cases was done. Immnohistochemical 
analysis of p63 antibody was done. 
 Lung carcinomas had a peak incidence in the group 40 to 70 years of 
age and was more common in males than in females. Most common clinical 
presentations were found to be cough, breathlessness and weight loss. 
Squamous cell carcinomas were found to be most commonly associated with 
history of smoking. The most common X ray findings were found to be mass 
lesion, opacity and consolidation. The most common findings at fibreoptic 
bronchoscopy were growth, unhealthy mucosa, necrotic material and narrowing 
of bronchus. 
 Histopathological examination showed 29 cases of pre invasive and 
invasive lesions - 6 pre invasive lesions (mild, moderate and severe dyplasias),  
12 squamous cell carcinomas, 8 adenocarcinomas, 1 in each of 
bronchioloalveolar carcinoma mucinous and non mucinous type and 1 large 
cell carcinoma. p63 immunoprotein status was studied in these cases and 
scoring was done according to the percentage of cells which showed p63 
positivity in each lesion. 
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 Most of the squamous cell carcinomas showed nuclear positivity for 
p63. p63 score showed progressive increase through mild to severe dysplasia. 
p63 score ranged from 0 to 3 in different histologic grades of squamous cell 
carcinoma. Poorly differentiated tumors showed decreased expression of p63 
immunostaining. 
 This confers that p63 immunostaining can be used to differentiate 
squamous and adenocarcinomas. It is also an important biological marker for 
squamous cell tumor progression and it can confer survival advantage. 
 
  
  
 
 Fig : 1         Mild Dysplasia - 100x 
 
 
Fig : 2         Mild Dysplasia - 400x 
 
 Fig : 3         Moderate  Dysplasia - 100x 
 
Fig : 4         Moderate Dysplasia - 400x 
 Fig : 5         Severe Dysplasia - 100x 
 
 
Fig : 6         Severe  Dysplasia - 400x 
 Fig : 7         Squamous Cell Carcinoma, Moderately Differentiated  – 100x 
 
Fig : 8        Squamous Cell Carcinoma, Moderately Differentiated  – 400x 
  
Fig : 9        Squamous Cell Carcinoma, Poorly Differentiated  – 100x 
 
 
Fig : 10        Squamous Cell Carcinoma, Poorly Differentiated  – 400x 
 Fig : 11         Adenocarcinoma – 100x 
 
 
Fig : 12         Adenocarcinoma – 400x 
  
Fig : 13         Mild Dysplasia – p63 Score 1 
 
 
Fig : 14         Moderate  Dysplasia – p63 Score 2 
 Fig : 15         Severe Dysplasia – p63 Score 3 
 
 
Fig : 16 Squamous Cell Carcinoma, Moderately Differentiated   
– p63 Score 3 
  
Fig : 17      Squamous Cell Carcinoma, Moderately Differentiated  – p63 
Score 3 
 
Fig : 18      Squamous Cell Carcinoma, Poorly Differentiated  – p63 Score 0 
  
 
 
Fig : 19         Adenocarcinoma – p63 Score 0 
 
 
 
 
S.
No AGE SEX HP NO COUGH SPUTUM HEMOPTYSIS CHEST PAIN BREATHLESSNESS
LOSS OF 
WEIGHT
H/O 
SMOKING
XRAY  FINDINGS 
FOB FINDINGS HP FINDINGS HP GRADE p63 SCORE
1 52 M 68/09 Y Y N N N N Y HAZINESS UNHEALTHY MUCOSA normal
2 77 F 210/09 N N Y Y N Y N BRONCHIECTASIS N non specific inflammation
3 36 M 211/09 Y Y Y Y Y N N CYSTIC CHANGES N non specific inflammation
4 60 M 212/09 Y Y Y N N Y Y OPACITY HYPERTROPHIED MUCOSA granulomatous lesion
5 65 M 506/09 Y Y N N N N Y OPACITY PURULANT SECRETIONS candidiasis
6 56 M 561/09 Y Y N N N N Y HAZINESS INFLAMMED MUCOSA squamous metaplasia
7 72 M 819/09 Y Y N Y Y N Y FIBROSIS INFLAMMED MUCOSA chronic Inflammation
8 50 M 890/09 Y Y Y N N N N N HYPERTROPHIED MUCOSA normal
9 38 M 943/09 Y Y N N N N Y HAZINESS UNHEALTHY MUCOSA normal
10 72 M 1157/09 Y Y N Y Y Y Y OPACITY NECROTIC MATERIAL severe dysplasia 3+
11 65 M 1367/09 Y Y N Y Y Y N CONSOLIDATION NARROWING OF BRONCHUS moderate dysplasia 2+
12 70 M 1368/09 Y Y N Y Y Y Y N GROWTH squamous cell carcinoma poorly differentiated 0
13 85 M 1465/09 Y Y N Y Y Y N OPACITY NECROTIC MATERIAL squamous cell carcinoma moderately differentiated 3+
14 54 M 5145/08 N N Y Y N Y N BRONCHIECTASIS N non specific inflammation
15 68 M 5146/08 Y Y N Y Y N Y HAZINESS NECROTIC MATERIAL inadequate material
16 47 M 5147/08 Y Y N N N N N HAZINESS HYPERTROPHIED MUCOSA chronic inflammation
17 54 M 5422/08 Y Y Y N N Y Y N INFLAMMED MUCOSA non specific inflammation
18 45 M 5676/08 Y Y N N N Y Y OPACITY GROWTH adenocarcinoma poorly differentiated 0
19 51 M 5677/08 Y Y N N Y Y N CONSOLIDATION GROWTH adenocarcinoma poorly differentiated 0
20 74 F 5981/08 Y Y N Y Y N Y FIBROSIS INFLAMMED MUCOSA chronic Inflammation
21 58 M 5982/08 Y Y Y N Y N N CAVITY N normal
22 55 M 5983/08 Y Y N N N N N CONSOLIDATION NARROWING OF BRONCHUS inadequate material
23 57 M 1601/09 Y Y Y N Y N N CAVITY N normal
24 45 M 1682/09 Y Y N N N N N HAZINESS HYPERTROPHIED MUCOSA chronic inflammation
25 57 M 1683/09 Y Y N N N Y Y OPACITY NARROWING OF BRONCHUS inadequate material
26 65 M 1892/09 Y Y N Y Y N Y HAZINESS NECROTIC MATERIAL inadequate material
27 60 M 1893/09 Y Y N Y Y Y N CAVITY PURULANT SECRETIONS inadequate material
28 40 M 2076/09 Y Y Y N N Y Y N INFLAMMED MUCOSA non specific inflammation
29 47 M 2308/09 Y Y Y N N Y Y N HYPERTROPHIED MUCOSA non specific inflammation
30 70 M 2429/09 Y Y N N N Y N OPACITY GROWTH adenocarcinoma moderately differentiated 0
31 23 M 2566/09 Y Y Y N Y N N HAZINESS N normal
32 60 M 2702/09 N N N Y Y Y Y CONSOLIDATION GROWTH squamous cell carcinoma moderately differentiated 2+
33 50 M 2860/09 N N N Y Y Y N OPACITY NARROWING OF BRONCHUS large cell ca 0
34 61 M 2861/09 N N N N Y Y Y HILAR PROMINENCE NARROWING OF BRONCHUS adenocarcinoma poorly differentiated 0
35 50 M 3428/09 Y Y Y N N N Y CYSTIC CHANGES N normal
36 60 M 3430/09 N N N N N Y N N UNHEALTHY MUCOSA BAC, mucinous type 0
37 57 M 3431/09 Y Y N N Y Y Y N HYPERTROPHIED MUCOSA normal
38 65 M 3775/09 Y Y Y N N N Y CYSTIC CHANGES N normal
39 48 M 3973/09 Y Y N Y Y Y Y OPACITY GROWTH inadequate material
40 55 M 3973/09 Y N N Y Y N N FIBROSIS HYPERTROPHIED MUCOSA normal
41 59 M 3972/09 Y Y Y N N N Y CAVITY N normal
42 48 M 4025/09 N N N Y Y Y N PLEURAL EFFUSION GROWTH adenocarcinoma 0
43 55 M 4026/09 Y Y N N N N Y CONSOLIDATION UNHEALTHY MUCOSA normal
44 50 M 4320/09 Y Y Y N N N Y CYSTIC CHANGES N normal
45 45 M 4321/09 Y N Y N Y Y Y HILAR MASS GROWTH squamous cell carcinoma moderately differentiated 3+
46 65 M 4454/09 Y N Y Y N N Y RIB METZ GROWTH squamous cell carcinoma moderately differentiated 1+
47 65 M 4455/09 N Y Y N Y Y Y HILAR MASS GROWTH squamous cell carcinoma moderately differentiated 3+
48 61 M 4603/09 N N N N N N Y HILAR PROMINENCE HYPERTROPHIED MUCOSA mild dysplasia 1+
49 40 M 4656/09 N N Y Y N Y N BRONCHIECTASIS N non specific inflammation
50 70 M 4796/09 Y Y N Y Y N Y CAVITY UNHEALTHY MUCOSA normal
51 49 M 4935/09 Y Y N N N N N HAZINESS N normal
52 60 M 4936/09 Y N N N N Y N CAVITY UNHEALTHY MUCOSA squamous cell carcinoma poorly differentiated 1+
53 72 M 4937/09 N N Y Y N Y N BRONCHIECTASIS N normal
54 28 M 4938/09 Y Y N N N N N HAZINESS N normal
55 35 M 5033/09 N Y Y N Y Y Y HILAR MASS GROWTH squamous cell carcinoma moderately differentiated 1+
56 58 M 5034/09 Y Y N N N N Y CONSOLIDATION N normal
57 46 M 5138/09 N N N N N N Y HILAR PROMINENCE HYPERTROPHIED MUCOSA mild dysplasia 1+
58 50 M 5515/09 N N N Y Y Y Y CONSOLIDATION GROWTH squamous cell carcinoma moderately differentiated 3+
59 24 F 5746/09 Y Y N Y Y Y N CAVITY PURULANT SECRETIONS inadequate material
60 50 M 5978/09 Y Y N Y Y N Y CAVITY UNHEALTHY MUCOSA normal
61 25 F 5979/09 Y Y N N N N N HAZINESS N normal
62 49 M 87/10 N N Y N N Y Y N N normal
63 45 M 245/10 N N Y N N Y Y N N normal
64 48 F 405/10 Y Y N N N Y N OPACITY NARROWING OF BRONCHUS BAC,non-mucinous type 0
65 32 F 543/10 Y Y N Y Y N Y CAVITY UNHEALTHY MUCOSA normal
66 49 M 623/10 Y Y N N N N N HAZINESS N normal
67 60 M 624/10 Y Y N N N Y Y OPACITY NARROWING OF BRONCHUS moderate dysplasia 2+
68 45 M 625/10 Y Y N Y Y N Y HAZINESS NECROTIC MATERIAL moderate dysplasia 2+
69 52 M 626/10 N N Y N N Y Y N N normal
70 40 M 627/10 N N Y N N Y Y N N normal
71 33 F 790/10 N N Y Y N Y N BRONCHIECTASIS N nonspecific inflammation
72 75 F 791/10 Y Y N Y Y Y N OPACITY GROWTH adenocarcinoma 0
73 48 F 792/10 Y Y N Y Y N N HAZINESS NECROTIC MATERIAL inadequate material
74 30 M 1037/10 Y Y N Y Y Y N CAVITY PURULANT SECRETIONS inadequate material
75 21 M 1038/10 N N Y N N Y Y N N normal
76 52 M 1039/10 Y Y N Y Y Y Y OPACITY GROWTH adenocarcinoma 0
77 70 F 1040/10 N N Y N N Y Y N N normal
78 40 M 1041/10 Y N N N Y Y Y HILAR MASS GROWTH squamous cell carcinoma moderately differentiated 1+
79 35 M 1549/10 Y Y N Y Y Y N CAVITY PURULANT SECRETIONS aspergillosis
80 58 M 1579/10 Y Y Y N Y Y N HILAR MASS NARROWING OF BRONCHUS granulomatous lesion
81 60 F 1653/10 Y Y N N N N N HAZINESS N normal
82 70 F 2027/10 Y N N N N Y N OPACITY NARROWING OF BRONCHUS adenocarcinoma 0
83 63 F 2028/10 Y Y N N N N N HAZINESS N normal
84 47 M 2029/10 N N Y N N Y Y N N normal
85 42 M 2030/10 Y N N N Y Y Y HILAR MASS GROWTH squamous cell carcinoma moderately differentiated 2+
86 70 M 2068/10 N N N Y Y Y N CONSOLIDATION GROWTH squamous cell carcinoma moderately differentiated 3+
87 29 F 2187/10 N N Y Y N Y N BRONCHIECTASIS N chronic inflammation
88 39 F 2188/10 Y Y N Y Y N Y CAVITY UNHEALTHY MUCOSA normal
89 60 M 2189/10 Y Y N N N N N HAZINESS N normal
90 65 F 2190/10 N N Y N N Y Y N N normal
91 63 F 2191/10 N N Y N N Y Y N N normal
92 65 M 2269/10 Y N N N N Y N CAVITY UNHEALTHY MUCOSA granulomatous lesion
93 40 M 2391/10 Y Y N Y Y N Y FIBROSIS INFLAMMED MUCOSA chronic Inflammation
94 47 M 2392/10 Y Y N N N N N HAZINESS N normal
95 42 M 2393/10 Y Y N N N N N HAZINESS N normal
96 63 F 2028/10 Y Y N N N N N HAZINESS N normal
97 70 M 4796/09 Y Y N Y Y N Y CAVITY UNHEALTHY MUCOSA normal
98 29 F 2187/10 N N Y Y N Y N BRONCHIECTASIS N chronic inflammation
99 45 M 2391/10 Y Y N Y Y N Y FIBROSIS INFLAMMED MUCOSA chronic Inflammation
100 50 M 4320/09 Y Y Y N N N Y CYSTIC CHANGES N normal
101 56 M 4026/09 Y Y N N N N Y CONSOLIDATION UNHEALTHY MUCOSA normal
102 65 M 2190/10 N N Y N N Y Y N N normal
103 50 M 623/10 Y Y N N N N N HAZINESS N normal
104 55 M 5978/09 Y Y N Y Y N Y CAVITY UNHEALTHY MUCOSA normal
105 45 M 245/10 N N Y N N Y Y N N normal
